Zinfandel
New Public Database of Short Structural Variants Helps Researchers Pinpoint ALS Risk Marker
Experts led by Duke neuroscientist Allen Roses developed the database hoping to boost researchers' ability to explore the role of short structural variants in complex diseases.
The group demonstrated the ability of a genetic algorithm to gauge whether cognitively normal people are at risk of near-term mental decline.
Researchers Use APOE-TOMM40 Haplotypes to Explain African-Americans' Unique Alzheimer's Risk Profile
Premium
NEW YORK (GenomeWeb) – Using a new in-phase assay, researchers led by Duke University's Allen Roses believe they have captured key differences in APOE and TOMM40 haplotypes between African-American, Caucasian, and West African populations.
Takeda, Zinfandel Launch TOMMORROW Trial to Evaluate Alzheimer's Onset Risk Algorithm, AD-4833
Premium
This article has been updated from a previous version to correct the pioglitazone dose to be used in the TOMMORROW trial. It is 0.8 mg/day, not 0.6 mg/day. Originally published Sept. 3.
Takeda, Zinfandel Evaluate Genetic Risk Algorithm Ahead of Alzheimer's Delay Study with Diabetes Rx
Premium
Originally published July 23.
Jun 19, 2013
Jan 12, 2011